ATE337787T1 - Exemestan zur behandlung von hormonabhängigen störungen - Google Patents

Exemestan zur behandlung von hormonabhängigen störungen

Info

Publication number
ATE337787T1
ATE337787T1 AT02727314T AT02727314T ATE337787T1 AT E337787 T1 ATE337787 T1 AT E337787T1 AT 02727314 T AT02727314 T AT 02727314T AT 02727314 T AT02727314 T AT 02727314T AT E337787 T1 ATE337787 T1 AT E337787T1
Authority
AT
Austria
Prior art keywords
exemestane
hormone
treatment
dependent disorders
disorders
Prior art date
Application number
AT02727314T
Other languages
English (en)
Inventor
Salle Enrico Di
Gabriella Piscitelli
Giorgio Massimini
Dinesh Purandare
Gans Hendrik Dekoning
Original Assignee
Pfizer Italia Srl
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl, Pharmacia & Upjohn Co Llc filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of ATE337787T1 publication Critical patent/ATE337787T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT02727314T 2001-01-26 2002-01-18 Exemestan zur behandlung von hormonabhängigen störungen ATE337787T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77091101A 2001-01-26 2001-01-26

Publications (1)

Publication Number Publication Date
ATE337787T1 true ATE337787T1 (de) 2006-09-15

Family

ID=25090093

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727314T ATE337787T1 (de) 2001-01-26 2002-01-18 Exemestan zur behandlung von hormonabhängigen störungen

Country Status (12)

Country Link
EP (1) EP1377298B1 (de)
JP (1) JP2004519490A (de)
AR (1) AR032268A1 (de)
AT (1) ATE337787T1 (de)
CA (1) CA2434611A1 (de)
DE (1) DE60214355T2 (de)
DK (1) DK1377298T3 (de)
ES (1) ES2269682T3 (de)
MX (1) MXPA03006607A (de)
PE (1) PE20020843A1 (de)
PT (1) PT1377298E (de)
WO (1) WO2002072106A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
WO2003017973A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
RU2227035C1 (ru) * 2003-02-05 2004-04-20 Павловский Алексей Васильевич Состав для профилактики и лечения фиброзно-кистозной мастопатии
EP1638573A4 (de) * 2003-06-20 2009-12-02 Merck & Co Inc Verwendung von selektiven cyclooxygenase-2-hemmern zur behandlung von endometriose
WO2007062093A2 (en) * 2005-11-22 2007-05-31 Incyte Corporation Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AU2007230716B2 (en) 2006-03-28 2012-05-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
WO2008019048A1 (en) * 2006-08-04 2008-02-14 Meditrina Pharmaceuticals Use of aromatase inhibitors for thining the endometrium or treating menorrhagia
RU2357733C1 (ru) * 2008-03-04 2009-06-10 Ольга Анатольевна Тихоновская Способ лечения функциональных кист яичников
CN101717393A (zh) * 2009-12-01 2010-06-02 陈依军 环己基2,5-二取代苯基醚的衍生物及其应用
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
EP3050878B1 (de) 2013-09-24 2021-10-27 FUJIFILM Corporation Neuartige stickstoffhaltige verbindung oder salz davon oder metallkomplex davon
AU2016381336A1 (en) 2015-12-30 2018-06-28 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
CN113712974B (zh) * 2021-08-20 2025-09-09 南京大学 阿司匹林作为唯一活性成分在制备治疗子宫内膜增生药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
GB8617107D0 (en) * 1986-07-14 1986-08-20 Erba Farmitalia 6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives
WO1994019365A1 (en) * 1993-02-18 1994-09-01 Farmitalia Carlo Erba Srl Fluorinated 4-aminoandrostadienone derivatives and process for their preparation
GB9313420D0 (en) * 1993-06-29 1993-08-11 Erba Carlo Spa Fluorinated 6-methylenandrosta-1,4-dien-3-one-derivatives and process for their preparations
CN1398189A (zh) * 1998-12-23 2003-02-19 G.D.西尔公司 用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
AU784617B2 (en) * 2000-05-15 2006-05-18 Pharmacia & Upjohn Company Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents
EP1317270A1 (de) * 2000-09-08 2003-06-11 Pharmacia Italia S.p.A. Exemestan zur behandlung von auf östrogen abhängigen krebs

Also Published As

Publication number Publication date
WO2002072106A3 (en) 2003-10-30
DE60214355T2 (de) 2007-08-30
EP1377298A2 (de) 2004-01-07
EP1377298B1 (de) 2006-08-30
AR032268A1 (es) 2003-10-29
DK1377298T3 (da) 2007-01-02
DE60214355D1 (de) 2006-10-12
WO2002072106A2 (en) 2002-09-19
JP2004519490A (ja) 2004-07-02
PT1377298E (pt) 2006-12-29
MXPA03006607A (es) 2003-09-22
ES2269682T3 (es) 2007-04-01
PE20020843A1 (es) 2002-09-25
CA2434611A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60317061D1 (de) Ibandronsäure zur behandlung und vorbeugung von osteoporose
DE69918222D1 (de) Intranasale Zubereitungen zur Behandlung sexueller Störungen
DE60233718D1 (de) Wasserbasierendes hydrophobiermittel zur behandlung von substraten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60233186D1 (de) Verbessertes System zur Behandlung von Elementarschwefel-Rückständen
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE254913T1 (de) Diacerein zur behandlung von psoriasis
DK1377298T3 (da) Exemestan til behandling af hormon-afhængige lidelser
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1377298

Country of ref document: EP

REN Ceased due to non-payment of the annual fee